PureTech Health plc announced that the U.S. Food and Drug Administration has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech Health plc announced that the U.S. Food and Drug Administration has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.